Depixus® Raises EUR 30.6M (USD 35.4M) in Series A Financing
The financing will support development of a commercial instrument system based on the company’s proprietary and disruptive MAGNA™ technology.
Read MoreNovel technology expected to greatly advance the burgeoning field of dynamic genomics
Wide range of possible translational and clinical applications, including virology and epigenetic biomarker discovery for liquid biopsy tests
Read More